Read It Nothing New
( This Biotech Will Get Sickle Cell Approved, Has 18 Drug Approvals, BLUE None.)
See it Market
This Week In IPOs: “Risk-Off”, Boutique Investment Banking And Sickle Cell Disease
August 10, 2015 Investing Research
( GBT )
GBT is developing the initial product candidate, GBT440, as a once-daily, oral prophylactic therapy for sickle cell disease.GBT plans to explore the treatment of more indications, notably hypoxemic pulmonary disorders and hereditary angioedema.
Highlights. Sickle Cell Disease ,Severe disease with major unmet medical need, large market opportunity. Highly experience team with successful track record in developing and commercializing drugs. Co. has contributed to 18 drug approvals
Links on Stocktwits, The Fly 24/7 Wall Street
What to Expect from Exelixis (EXEL) This Earnings Season?
Yahoo Finance - 1 day ago
The company has an impressive track record, having beat estimates comfortably in the last four quarters
Date Firm Action Rating Price Target Actions
6/18/2015 Canaccord Genuity Boost Price Target Buy $19.00 View Rating Details Tweet This Rating Share This Rating on StockTwits
6/18/2015 Cantor Fitzgerald Reiterated Rating Buy $14.00